0.773
price down icon18.24%   -0.1725
after-market Handel nachbörslich: .76 -0.013 -1.68%
loading

Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten

pulisher
Mar 13, 2025

Avenue Therapeutics stock hits 52-week low at $0.9 amid downturn - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Mar 13, 2025
pulisher
Mar 07, 2025

Avenue Therapeutics granted Nasdaq extension, faces AnnJi dispute By Investing.com - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 07, 2025

Avenue Therapeutics granted Nasdaq extension, faces AnnJi dispute - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Avenue Therapeutics Annji Intends To Terminate License Agreement With Co -March 07, 2025 at 04:36 pm EST - Marketscreener.com

Mar 07, 2025
pulisher
Mar 07, 2025

Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld Online

Mar 07, 2025
pulisher
Mar 05, 2025

Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade - Nasdaq

Mar 05, 2025
pulisher
Mar 04, 2025

SEC Form 424B5 filed by Y-mAbs Therapeutics Inc. - Quantisnow

Mar 04, 2025
pulisher
Mar 03, 2025

Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 40.5% in February - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Increase in Short Interest - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

KESTRA MEDICAL TECHNOLOGIES, LTD. Prices IPO at $14.00-$16.00 Per Share (KMTS) - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

Short Interest in ArrowMark Financial Corp. (NASDAQ:BANX) Expands By 62.6% - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

American Rebel Holdings, Inc. (NASDAQ:AREB) Sees Large Growth in Short Interest - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

Arbe Robotics Ltd. (NASDAQ:ARBE) Short Interest Up 56.5% in February - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down After Analyst Downgrade - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Avenue Therapeutics stock hits 52-week low at $1.22 - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Avenue Therapeutics stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Avenue Therapeutics (NASDAQ:ATXI) vs. Teva Pharmaceutical Industries (NYSE:TEVA) Head to Head Review - Defense World

Feb 28, 2025
pulisher
Feb 28, 2025

Wedbush Lowers Earnings Estimates for Travere Therapeutics - Defense World

Feb 28, 2025
pulisher
Feb 12, 2025

The Surprise Surge: How Travere Therapeutics Defied Wall Street Trends - Jomfruland.net

Feb 12, 2025
pulisher
Feb 12, 2025

Avenue Therapeutics stock hits 52-week low at $1.5 amid challenges - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

ATXIAvenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights - br.ADVFN.com

Feb 11, 2025
pulisher
Feb 06, 2025

Sionna Therapeutics Prices Upsized Initial Public Offering - GlobeNewswire

Feb 06, 2025
pulisher
Feb 05, 2025

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - Yahoo Finance

Feb 05, 2025
pulisher
Feb 05, 2025

Here’s Why Third Avenue Small-Cap Value Fund Re-established a Position in Five Point Holdings (FPH) - Yahoo Finance

Feb 05, 2025
pulisher
Jan 28, 2025

Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice - ACCESS Newswire

Jan 28, 2025
pulisher
Jan 28, 2025

Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com

Jan 28, 2025
pulisher
Jan 27, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Jan 27, 2025
pulisher
Jan 27, 2025

Trajan Group Director Increases Stake Through Options - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

How Are Things Looking For Zeta Global Holdings Corp (NYSE: ZETA) For The Short Term? - Stocks Register

Jan 27, 2025
pulisher
Jan 27, 2025

Park Avenue Securities LLC Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World

Jan 27, 2025
pulisher
Jan 27, 2025

13,028 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Park Avenue Securities LLC - Defense World

Jan 27, 2025
pulisher
Jan 27, 2025

Park Avenue Securities LLC Buys Shares of 1,684 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Park Avenue Securities LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World

Jan 26, 2025
pulisher
Jan 26, 2025

Assenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Assenagon Asset Management S.A. Sells 65,316 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Jan 25, 2025
pulisher
Jan 24, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 24, 2025
pulisher
Jan 24, 2025

FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan

Jan 24, 2025
pulisher
Jan 24, 2025

Wall Street-Heavily Traded - WDRB

Jan 24, 2025
pulisher
Jan 24, 2025

PLRX (Pliant Therapeutics) Momentum Rank : 7 (As of Jan. 24, 2025) - GuruFocus.com

Jan 24, 2025
pulisher
Jan 24, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Decreased by Assenagon Asset Management S.A. - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

Fortune Brands plans Deerfield headquarters expansion, hundreds of new jobs; ‘A great endorsement of Lake County’ - Chicago Tribune

Jan 23, 2025
pulisher
Jan 22, 2025

Healthcare Triangle Faces Potential Delisting, Plans Annual Meeting - MSN

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Cuts Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Park Avenue Securities LLC - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Sells 889,884 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

Another strong year for K Street heading into Trump 2.0, tax fights - POLITICO

Jan 22, 2025
pulisher
Jan 21, 2025

Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World

Jan 21, 2025
pulisher
Jan 21, 2025

Hennion & Walsh Asset Management Inc. Takes Position in Autolus Therapeutics plc (NASDAQ:AUTL) - Defense World

Jan 21, 2025
pulisher
Jan 21, 2025

Assenagon Asset Management S.A. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Jan 21, 2025
pulisher
Jan 19, 2025

AVTX (Avalo Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 19, 2025
pulisher
Jan 19, 2025

JPMorgan Chase & Co. Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jan 19, 2025
pulisher
Jan 19, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - Defense World

Jan 19, 2025
pulisher
Jan 17, 2025

Coeptis Therapeutics (Nasdaq: COEP) Emerges as a Biopharma Innovator Leveraging AI-Driven Marketing - Barchart

Jan 17, 2025
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Kapitalisierung:     |  Volumen (24h):